Is Lipoprotein-Associated Phospholipase A2 a Link between Inflammation and Subclinical Atherosclerosis in Rheumatoid Arthritis?

Table 4

Results of simple regression models among 71 patients with early RA with the concentration of Lp-PLA2 at T5 as the dependent variable.

	Lp-PLA2 at T5
	β	95% CI	value
IMT T5 (n = 66)	4.4/mm	−2.7; 11.5	0.22
FMD T5 (n = 66)	−1.7/%	−3.8; 0.4	0.10
Non-HDL-cholesterol T5 (n = 61)	19.0/mmolL^−1	10.5; 27.5	0.001
HDL T5 (n = 61)	−31.8/mmolL^−1	−50.3; −13.3	0.001
Cholesterol T5 (n = 61)	11.5/mmolL^−1	2.1; 20.8	0.02
Ever smoking (n = 66)	0.4/year	−0.3; 1.1	0.26
BMI T5 (n = 66)	2.5/unit	0.3; 4.7	0.03
SCORE T5 (n = 61)	3.6/unit	−2.0; 9.2	0.21
Reynolds Risk Score T5 (n = 39)	2.8/unit	−0.2; 5.7	0.06

RA: rheumatoid arthritis; Lp-PLA2: lipoprotein-associated phospholipase A2; IMT: intima media thickness; FMD: flow mediated dilation; HDL: high-density lipoproteins; BMI: body mass index.